Keyvan Rezaï

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

Céline Berthon, Emmanuel Raffoux, Xavier Thomas et al. · The Lancet Haematology · 2016 · 425 citations

Hematological Malignancy, Translational Medicine, Acute Leukaemia +14

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

Sandy Amorim, Anastasios Stathis, Mary Gleeson et al. · The Lancet Haematology · 2016 · 420 citations

Hematological Malignancy, Lymphoid Neoplasia, Translational Medicine +9

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network

Carole Soussain, Sylvain Choquet, Marie Blonski et al. · European Journal of Cancer · 2019 · 305 citations · Full text

Neuro-oncology, Primary Vitreoretinal Lymphoma, Lymphoid Neoplasia +6

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors

Jeremy Lewin, Jean‐Charles Soria, Anastasios Stathis et al. · Journal of Clinical Oncology · 2018 · 267 citations

OTX015 (MK‐8628), a novel BET inhibitor, displays <i>in vitro</i> and <i>in vivo</i> antitumor effects alone and in combination with conventional therapies in glioblastoma models

Caroline Berenguer‐Daizé, Lucile Astorgues‐Xerri, Elodie Odore et al. · International Journal of Cancer · 2016 · 147 citations · Full text